{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:17:25Z","timestamp":1789168645792,"version":"build-2803163510"},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Dermatology"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The treatment of canine chronic cutaneous lupus erythematosus (CCLE) variants generally requires immunosuppression, which often results in potentially severe adverse effects. Janus kinase inhibitors, like oclacitinib, might be a valuable treatment option due to their rapid inhibition of the action of interferons known to be relevant in the pathogenesis of CCLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To report the efficacy and safety of oral oclacitinib for the treatment of canine CCLE variants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Seven dogs were diagnosed with CCLE based on clinical signs and compatible histopathological findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Oclacitinib was administered at the induction dosage of 0.45\u2009mg\/kg twice daily to 1.8\u00a0mg\/kg once daily. The response to treatment was graded as \u2018good\u2019 when there was \u226550% lesion reduction, or as \u2018complete remission\u2019 if all active lesions had resolved. Complete blood counts were performed at variable intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A complete remission of all lesions was obtained in the dog with exfoliative cutaneous lupus erythematosus, both dogs with mucocutaneous lupus erythematosus and three of four dogs with facial discoid lupus erythematosus (FDLE); a good response was seen in the remaining dog with FDLE. The first visible improvement of signs was seen within 2\u2010to\u20103\u2009weeks, while the time to complete remission was around 2\u2009months. Clinical adverse effects were not seen, and haematological parameters remained within the reference range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Relevance<\/jats:title>\n                    <jats:p>Oclacitinib may be considered an effective treatment option for different variants of canine CCLE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/vde.13128","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T01:22:14Z","timestamp":1665710534000},"page":"53-58","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases"],"prefix":"10.1111","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7176-5487","authenticated-orcid":false,"given":"Richard G.","family":"Harvey","sequence":"first","affiliation":[{"name":"Willows Referral Services  Shirley, Solihull UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Olivr\u012b","sequence":"additional","affiliation":[{"name":"Veterinary Dermatology Riga SIA Olivry Consulting  Riga Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1230-9526","authenticated-orcid":false,"given":"Tatiana","family":"Lima","sequence":"additional","affiliation":[{"name":"North Downs Specialist Referral  Bletchingley UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1399-0034","authenticated-orcid":false,"given":"Thierry","family":"Olivry","sequence":"additional","affiliation":[{"name":"Veterinary Dermatology Riga SIA Olivry Consulting  Riga Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0272-0"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-2427(79)90009-6"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-018-1446-8"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crimmu.2021.03.003"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2021.AB001"},{"key":"e_1_2_9_7_1","first-page":"1","article-title":"A randomized, double\u2010blinded, placebo\u2010controlled crossover study evaluating 0.03% tacrolimus ointment monotherapy in the treatment of discoid lupus erythematosus in dogs","volume":"3","author":"Messinger L","year":"2017","journal-title":"SOJ Vet Sci"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12088"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12458"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12743"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.13063"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12852"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12194"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.257.5.507"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.13053"}],"container-title":["Veterinary Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vde.13128","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vde.13128","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vde.13128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T05:53:17Z","timestamp":1692424397000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vde.13128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1111\/vde.13128"],"URL":"https:\/\/doi.org\/10.1111\/vde.13128","archive":["Portico"],"relation":{},"ISSN":["0959-4493","1365-3164"],"issn-type":[{"value":"0959-4493","type":"print"},{"value":"1365-3164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"assertion":[{"value":"2022-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}